Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
235
resultados
Última actualización
20/03/2026 [06:51:00]
Resultados 75 a 100 de 235
Resumen de: US20260069542A1
The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids.
Resumen de: US20260069669A1
The disclosure provides an oral vaccine for enhancing cancer immunotherapy, which includes a complex of β-glucan and mRNA and lipid nanoparticles, wherein the mRNA includes a coding region of a tumor antigen, and the lipid nanoparticles encapsulate the complex of β-glucan and mRNA.
Resumen de: US20260069541A1
Disclosed herein are lipid nanoparticles for the delivery of active agents, including nucleic acids, as well as methods of making using thereof.
Resumen de: US20260069539A1
Compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications are disclosed.
Resumen de: US20260069538A1
In various embodiments drug delivery vehicles and uses thereof are provided. In certain embodiments the drug delivery vehicles comprise: 1) a silicasome comprising a mesoporous silica nanoparticle coated with a lipid bilayer and further comprising a CXCR4 antagonist; or 2) a liposome comprising a lipid bilayer comprising where said liposome further comprises a CXCR4 antagonist. In certain embodiments the CXCR4 antagonists are selected from the group consisting of AMD3100, AMD3465, and AMD070.
Resumen de: US20260069540A1
Nanoparticle compositions for delivery of nucleic acids to subjects including aminoalkyl branched lipid-like molecules as carriers, and therapeutic or immunogenic nucleic acid agents enclosed within the nanoparticle containing are described. Also provided are methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects.
Resumen de: US20260069536A1
The present disclosure provides compositions, systems, devices, and methods for the delivery of therapeutics. Particularly, the disclosure provides composition, systems, and devices of the delivery of Janus kinase (JAK) inhibitors and uses thereof, such as for inhibiting allograft rejection or treating autoimmune diseases.
Resumen de: US20260070960A1
Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-domain antibodies were isolated from dromedary camel (VHH) antibody libraries by panning the library with an E6- or E7-derived peptide in complex with HLA-A*02:01. Use of the single-domain antibodies for the detection and treatment of HPV-associated cancers and pre-cancerous lesions is also described.
Resumen de: US20260070985A1
Disclosed are nanoparticles comprising directionally attached antibodies and compositions for use in locoregional delivery, including intra-tumoral and transarterial chemoembolization (TACE), and methods of making the nanoparticles. Also disclosed are methods for treating a subject in need thereof the compositions described.
Resumen de: US20260070935A1
Described herein, in part, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and/or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasize to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.
Resumen de: US20260070964A1
The present disclosure relates to a combination therapy comprising an anti-VEGF antibody, a nanoparticle formulated plasmid comprising an IL-12 coding nucleic acid, and, optionally, at least one adjunctive chemotherapeutic drug, and methods of treatment using such combination therapies and/or compositions.
Resumen de: AU2026201122A1
Abstract The invention relates to biocompatible polysaccharide-based nanocapsule templated on oil core of diameter not exceeding 1 μm, stabilized without low molecular weight surfactants. The nanocapsule shows long-term stability in an aqueous suspension and is able to highly efficient encapsulation of hydrophobic compounds. Abstract eb b s t r a c t e b
Resumen de: AU2024367887A1
The present invention relates to a novel ionizable lipid compound represented by Formula (I) or a salt thereof, and a lipid nanoparticle containing the same. The lipid nanoparticle containing the novel ionizable lipid compound according to the present invention has an excellent nucleic acid encapsulation efficiency and has a high efficiency of cellular delivery of nucleic acid.
Resumen de: AU2025308132A1
The present invention relates to a nanoformulation comprising L-leucyl-L-leucine methyl ester (LLOMe) and a polymer for wound healing, which promotes multiple molecular signaling pathways essential for faster wound healing. The nanoformulation offers faster and improved wound and tissue healing, axon regeneration, antiviral immunity, stem cell proliferation, embryonic development, and anti-aging effects.
Resumen de: AU2024366071A1
The present invention relates to a novel ionizable lipid compound represented by formula (I), or a salt thereof, and lipid nanoparticles comprising same. The lipid nanoparticles comprising the novel ionizable lipid compound, according to the present invention, have excellent nucleic acid encapsulation efficiency and high nucleic acid cell delivery efficiency.
Resumen de: AU2024341673A1
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) or formula (II) and methods for preparing the stabilizing agents and the lipid nanoparticle are provided.
Resumen de: AU2024342034A1
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.
Resumen de: AU2024340379A1
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition including: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.
Resumen de: AU2024326546A1
Described is a nanopore that is selectively convertible between an open form and a closed form using light, a method for producing such a nanopore, a method of modulating the flow of one or more substances through the nanopore, the use of the nanopore in modulating ionic flow across an amphiphilic membrane, a device comprising the nanopore, use of the nanopore as an ionotronic component, use of the nanopore in bio-computation and/or bioionotronics, a method of transmitting information using the nanopore, and method of receiving information comprising the nanopore, and an ionotronic component comprising the nanopore.
Resumen de: AU2024325184A1
The present invention relates to a drug delivery material and an application thereof. Specifically provided is a nanoparticle composition comprising a lipid component, the lipid component comprising a compound represented by formula (I). The nanoparticle composition of the present invention is delivered only at the site of administration.
Resumen de: WO2026054725A1
The invention relates to a pharmaceutical composition comprising tamoxifen-loaded mesenchymal stem cell-derived exosomes enriched with miR-342 for use in the pharmaceutical and vaccine industry, in the treatment of cancer, in the treatment of breast cancer, in overcoming tamoxifen resistance in the treatment of estrogen receptor positive breast cancer using tamoxifen.
Resumen de: WO2026052854A1
The disclosure provides nanoparticle lipid compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) a sterol; and (c) a stabilizer. The disclosure provides methods for preparing the lipid nanoparticle compositions and uses of the lipid nanoparticle or the pharmaceutical composition for preventing, treating, or ameliorating conditions or diseases.
Resumen de: WO2026052844A1
P2023-0430-WO 84 ABSTRACT The disclosure provides nanoparticle lipid compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) a sterol; and (c) a stabilizer. The disclosure provides methods for preparing the lipid nanoparticle compositions and uses of the lipid nanoparticle or the pharmaceutical composition for preventing, treating, or ameliorating conditions or diseases.
Resumen de: WO2026052839A1
This invention relates to targeting fusion proteins based on molecules which bind serum proteins, such as serum protein receptors. The invention also relates to amphipathic structures linked to the targeting fusion proteins. The invention also relates to methods of targeting and therapeutic methods using the fusion proteins and/or amphipathic structures.
Nº publicación: WO2026052938A1 12/03/2026
Solicitante:
SWANSEA UNIV [GB]
SWANSEA UNIVERSITY
Resumen de: WO2026052938A1
Pancreatic Disorders The invention relates to a nanoparticle that is suitable for use as a nanoscopic vector for delivering therapeutic agents for use in treating a pancreatic disorder; a pharmaceutical or veterinary composition for use in treating a pancreatic disorder comprising said vectors; and the use of said vectors for treatment of a pancreatic disorder. The invention further relates to a method of treating a pancreatic disorder employing the use of said vectors or pharmaceutical compositions.
BOPI
Sede Electrónica
